For UAE, Kuwait, Bahrain, Qatar and Oman Healthcare Professionals Only

WAINUA® (eplontersen) Logo
 

WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

close-icon

DOSING & ADMINISTRATION

WAINUA autoinjector puts the power of control in the hands of patients and HCPs

WAINUA (eplontersen) Autoinjector

CONVENIENT SELF-ADMINISTRATION

Autoinjector designed for use by the patient or a caregiver, at home or on the go1

Proper storage required.

Administered In 10 Seconds Once a Month

10 SECONDS ONCE A MONTH*

Administration by the patient, caregiver, or HCP1
WAINUA (eplontersen) No Infusion Center

DESIGNED TO FIT THEIR LIFE

No infusion center, local clinic, or lab monitoring required1

  1. *Following preparation.

Configure Image Component
strong-wainua
strong-wainua

WAINUA dosage and administration1:

  • Recommended dose: 45 mg in a single-dose autoinjector. No dose adjustments required
  • Missed dose: Administer WAINUA as soon as possible after a missed dose. Resume dosing at monthly intervals from the date of the most recently administered dose
  • Vitamin A supplementation: Patients should supplement with the recommended daily allowance of vitamin A while taking WAINUA (see Important Safety Information below)

Storing WAINUA1:

  • In the original carton, protected from light
  • In the refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze
  • At room temperature up to 30°C (86°F) for up to 6 weeks; if not used within 6 weeks, discard WAINUA. Do not expose to heat
Configure Image Component
strong-wainua
strong-wainua

Watch this instructional video on how to administer WAINUA

Edit Video Component

REFERENCE

  1. 1. WAINUA® (eplontersen) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2025.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

  • Reduced Serum Vitamin A Levels and Recommended Supplementation WAINUA leads to a decrease in serum vitamin A levels. Supplement with recommended daily allowance of vitamin A. Refer patient to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.

ADVERSE REACTIONS

Most common adverse reactions (≥9% in WAINUA-treated patients) were vitamin A decreased (15%) and vomiting (9%).

INDICATION

WAINUA injection, for subcutaneous use, 45 mg is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis
in adults.

 

Loading......

Modal Window Component Section Begins
Modal Window Component Section Ends
Configure Footer Reference Component
Reference
Back to top